Company Brief
Cybin Corp is developing products and protocols with some of the brightest minds in the psychedelic, pharmaceutical and nutraceutical sectors.
We are led by an experienced team who has run multiple clinical trials and has successfully brought many new drugs to market.
Our IP strategy revolves around psychedelic delivery mechanisms, synthetic compounds, extraction methods, isolation of chemical compounds, new drug formulations and protocol regimens.
We view psychedelic medicines derived from mushrooms as boosters for the brain that can potentially retrain thought processes and break negative patterns all while looking at non-psychedelic medical mushroom extracts as the next wave of super nutraceuticals that can optimize overall health.